Ventripoint Announces Non-Brokered Units Private Placement

Executive Summary

• Ventripoint Diagnostics Ltd. announced a non‑brokered private placement of up to 5,000,000 units at $0.10 per unit, targeting gross proceeds of up to $500,000.
• Each unit consists of one common share and one common share purchase warrant exercisable at $0.13 for 24 months; the company may issue additional finder’s warrants equal to up to 8% of gross proceeds.
• Proceeds will be used for sales and marketing activities, hiring key personnel, and general working capital.

Key Details

• Offering Size: Up to 5,000,000 units (each $0.10) → maximum gross proceeds of $500,000.
• Unit Composition: 1 common share + 1 common share purchase warrant.
• Warrant Terms: Each warrant allows purchase of one common share at $0.13 for a period of 24 months from closing. The company may accelerate expiry if the share trades at $0.26 for ten consecutive days (including non‑trading days) with 30‑day notice.
• Finder’s Fee/Warrants: Up to 8% of gross proceeds may be paid in cash and/or issued as additional finder’s warrants, exercisable at $0.13 per share for 24 months.
• Use of Proceeds: Funding operational costs related to sales & marketing, addition of key personnel, and general working capital.
• Holding Period: All securities issued are subject to a lock‑up of four months plus one day from the closing date.
• Regulatory Conditions: Offering is subject to TSXV Venture Exchange acceptance; securities will not be registered under U.S. federal securities laws and cannot be offered or sold in the United States absent an exemption or registration.

Notable Quotes

(No executive quotes were included in the release.)